KEYNOTE-427 study looking at first-line pembrolizumab monotherapy

• Date : 16/02/2019
• 3    
  0

CheckMate 214: nivolumab + ipilimumab or sunitinib in patients

• Date : 16/02/2019
• 2    
  0

Latest from CheckMate 650: nivolumab plus ipilimumab

• Date : 16/02/2019
• 1    
  0

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy

• Date : 16/02/2019
• 1    
  0

Updates from the BCON trial: longterm outcomes of hypoxia modification

• Date : 16/02/2019
• 0    
  0

Penile squamous cell carcinoma is genomically

• Date : 16/02/2019
• 0    
  0

Analysis of acute toxicity from PACE-B: a trial comparing SBRT

• Date : 16/02/2019
• 0    
  0

STREAM trial: enzalutamide and androgen deprivation therapy

• Date : 16/02/2019
• 0    
  0

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo

• Date : 16/02/2019
• 0    
  0

Latest from Tivo-3: tivozanib for refractory advanced renal cell carcinoma

• Date : 16/02/2019
• 0    
  0

CB-839 in combination with cabozantinib in patients

• Date : 16/02/2019
• 0    
  0

Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma

• Date : 16/02/2019
• 0    
  0

Roundup of renal cancer research

• Date : 16/02/2019
• 0    
  0

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

• Date : 16/02/2019
• 0    
  0

CHEIRON study: docetaxel plus enzalutamide versus docetaxel

• Date : 16/02/2019
• 0    
  0

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

• Date : 16/02/2019
• 0    
  0

treatment and management of hormone-sensitive metastatic prostate cancer

• Date : 16/02/2019
• 0    
  0

Updates on non-metastatic castration-resistant prostate cancer (CRPC)

• Date : 16/02/2019
• 0    
  0

Updates on treatment and management of bladder cancer

• Date : 16/02/2019
• 0    
  0

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

• Date : 16/02/2019
• 0    
  0

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib

• Date : 16/02/2019
• 0    
  0

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

• Date : 16/02/2019
• 0    
  0

Congrès ESMO 2026

• Date : 23/10/2026
• 186    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 10/12/2025
• 343    
  0

SABCS 2025 Symposium

• Date : 09/12/2025
• 5731    
  0

Congrès ESMO Asie 2025

• Date : 05/12/2025
• 401    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 13/11/2025
• 641    
  0